Levi & Korsinsky Alerts Pacira Investors About Class Action Lawsuit Deadlines

Pacira BioSciences Class Action Lawsuit Alert

Investors in Pacira BioSciences, Inc. should take heed of a significant class action lawsuit notification from Levi & Korsinsky, LLP. This alert serves as an important reminder concerning the ongoing securities litigation that may impact shareholders negatively. The firm is particularly focusing on the period between August 2, 2023 and August 8, 2024, during which it alleges that investors encountered substantial losses attributable to alleged securities fraud.

Background on Pacira BioSciences

Pacira BioSciences, known for its innovative pharmaceutical solutions, primarily generates revenue from its flagship product, Exparel. Recent developments, particularly a lawsuit related to patent infringement against eVenus, have raised concerns among investors. In August 2024, Pacira revealed unsettling news via a press release indicating that its key patent, U.S. Patent No. 11,033,495, was found invalid in court. This ruling essentially means that eVenus is not infringing on the patent, which significantly undermines Pacira’s market position as it relates to Exparel, a product responsible for approximately 80% of the company’s revenue.

Details of the Lawsuit

The class action claim aims to recover losses suffered by investors who held Pacira shares during the stated timeframe. Following the public disclosure of the patent litigation results, Pacira's share price plummeted from $22.36 on August 8, 2024, to just $11.70 the very next day—a staggering drop of over 47%. Such dramatic shifts in stock value have prompted lawyers to investigate possible securities fraud that misled investors regarding the stability and prospects of Pacira’s earnings.

Important Deadlines

For those affected, it is crucial to note that the deadline to request lead plaintiff status in this case is set for March 14, 2025. If you suffered financial losses due to fluctuations in Pacira's stock and believe you have a case, it’s advisable to reach out. Participation in this class action holds no financial obligation on your part to secure any compensation that may be awarded should the case progress favorably.

How to Proceed

If you feel your investments in Pacira have been compromised, you can obtain more information about the legal proceedings and how to participate by visiting the official Levi & Korsinsky website. Additionally, interested investors can contact one of the firm's attorneys directly via email or telephone to discuss next steps and potential eligibility for compensation.

Why Choose Levi & Korsinsky?

Levi & Korsinsky is recognized for its commitment to safeguarding investor rights and has accumulated a formidable track record over the past two decades. The firm has successfully recovered hundreds of millions of dollars for aggrieved shareholders and has consistently ranked among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

For investors in Pacira BioSciences, staying informed about these developments is crucial. Engaging early with legal representatives can ensure your rights are protected throughout this litigation process. Don’t miss out on the opportunity to seek redress if you have suffered due to this alleged fraud.